Nascent Biotech Receives Clearance from FDA to Begin Phase I Human Trials in Brain Cancer
Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic antibodies toward the paratope of malignant associated autologous anti-vimentin antibody, CLN-IgG (Pritumumab)
Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference
The Economist: Closing In On Cancer
Nascent Biotech Retires Liabilities with Non-Dilutive Funding
Nascent Biotech and Hisun Announce an Exclusive License Agreement for the Development and Commercialization of Nascent’s Primary Asset, Pritumumab, in Mainland China
Get the Nascent Newsletter
Stay in touch with news from Nascent Biotech when you sign up for our free newsletter.
Contact Nascent
Communicate with Nascent Biotech the quick and easy way – through our contact form.